Includes information concerning suspected adverse reactions to Canadian marketed health products of pharmaceuticals, biologics (including blood products and therapeutic and diagnostic vaccines), natural health products, and radiopharmaceuticals, as reported to Health Canada through voluntary and mandatory reporting measures.

The human element is the principle cause of incidents and accidents in all technology industries; hence it is evident that an understanding of the interaction between humans and technology is crucial to the effective management of risk. Despite this, no tested model that explicitly and quantitatively includes the human element in risk prediction is currently available. Managing Risk: the Human Element combines descriptive and explanatory text with theoretical and mathematical analysis, offering important new concepts that can be used to improve the management of risk, trend analysis and prediction, and hence affect the accident rate in technological industries. It uses examples of major accidents to identify common causal factors, or “echoes”, and argues that the use of specific experience parameters for each particular industry is vital to achieving a minimum error rate as defined by mathematical prediction. New ideas for the perception, calculation and prediction of risk are introduced, and safety management is covered in depth, including for rare events and “unknown” outcomes Discusses applications to multiple industries including nuclear, aviation, medical, shipping, chemical, industrial, railway, offshore oil and gas; Shows consistency between learning for large systems and technologies with the psychological models of learning from error correction at the personal level; Offers the expertise of key leading industry figures involved in safety work in the civil aviation and nuclear engineering industries; Incorporates numerous fascinating case studies of key technological accidents. Managing Risk: the Human Element is an essential read for professional safety experts, human reliability experts and engineers in all technological industries, as well as risk analysts, corporate managers and statistical analysts. It is also of interest to professors, researchers and postgraduate students of reliability and safety engineering, and to experts in human performance. “...congratulations on what appears to be, at a high level of review, a significant contribution to the literature...I have found much to be admired in (your) research” Mr. Joseph Fragola – Vice President of Valador Inc. “The book is not only technically informative, but also attractive to all concerned readers and easy to be comprehended at various level of educational background. It is truly an excellent book ever written for the safety risk managers and analysis professionals in the engineering community, especially in the high reliability organizations...” Dr Feng Hsu, Head of Risk Assessment and Management, NASA Goddard Space Flight Center “I admire your courage in confronting your theoretical ideas with such diverse, ecologically valid data, and your success in capturing a major trend in them....I should add that I find all this quite inspiring . ...The idea that you need to find the right measure of accumulated experience and not just routinely used calendar time makes so much sense that it comes as a shock to realize that this is a new idea”, Professor Stellan Ohlsson, Professor of Psychology, University of Illinois at Chicago

Discover the world of pharmacovigilance, where patient safety takes center stage. In "Vigilance Unleashed: From Adverse Events to Patient Protection," we delve into the science and practices that safeguard patients from medication and medical devices' risks. Unravel the historical background, regulatory frameworks, and international collaborations that shape pharmacovigilance practices. From identifying adverse drug reactions to embracing emerging technologies and patient-centered approaches, this comprehensive guide equips readers with essential knowledge to navigate the dynamic landscape of pharmacovigilance confidently. Join us on this journey to champion patient safety and unleash the power of vigilance in healthcare.

There is ample evidence that children and adolescents in large numbers are actively using integrative (complementary and alternative) therapies. Various studies now indicate that over 50% of pediatricians surveyed would refer a patient for integrative therapy, and they would welcome more natural therapies for children provided they were safe and effective. However, there has been little training for pediatricians in this area. Integrative Pediatrics addresses these issues and provides guidelines for pediatricians, parents, and general audiences in a balanced, evidence-based manner. In this volume in the Weil Integrative Medicine Library series, the authors describe a rational and evidence-based approach to the integrative therapy of childhood disorders and well-child care, integrating the principles of alternative and complementary therapies into the principles and practice of conventional pediatrics. The authors examine what works and what doesn't and offer practical guidelines for physicians to incorporate integrative medicine into their practice and how to advise patients and their parents on reasonable and effective therapies. The text also covers areas of controversy and identifies areas of uncertainty where future research is needed. Chapters also cite the best available evidence for both safety and efficacy of all therapies discussed. The series editor is Andrew Weil, MD, Professor and Director of the Program of Integrative Medicine at the University of Arizon. Dr. Weil's program was the first academic program in the US and he is the major name in integrative medicine in the US, and well-known around the world. His program's stated goal is "to combine the best ideas and practices of conventional and alternative medicine into cost effective treatments without embracing alternative practices uncritically."

This is the long-awaited third edition of the most comprehensive compilation of drug information resources available. A co-publication with the Medical Library Association, it draws on industry expert Bonnie Snow's 30+ years of experience with pharmaceutical information needs and applications. Snow reviews 400+ print and electronic resources.More than a bibliography, this readable guide brings together the best resources plus practical advice on everything from expert search techniques to core collections for libraries. Subject areas covered include: pharmaceutical technology; legal and regulatory issues world-wide; industrial pharmacy; market research; product guides and prescribing information in the global marketplace; drug interactions; drug effects on pregnancy, lactation, and reproduction; pharmacovigilance; and much, much more. Completely revised, reorganized, and updated, the third edition focuses on information sources not covered elsewhere. Absolutely unique in its value as both a desk reference and a text for classroom use or self-study, this edition manages to meet the needs of students, information professionals, health care providers, and pharmacy practitioners.

In times of situational therapeutic impasse, health care professionals (HCPs) are under pressure to conduct off-label, unlicensed and compassionate drug use—generally summarized under the term non-licensed drug use (NDU). Liability, contractual and penal risks pose a problem when treating a patient in a non-licensed way. There is a knowledge gap about institutional and governmental methods to resolve these problems. Different countries have developed strategies to manage NDU. Vanessa Platé gives a comprehensive overview of practices Canada, the U.S., the U.K., Japan, France, Germany, Switzerland, Austria, and the transnational E.U. A must-read for everyone interested in the discussion on how to administer the best treatment, especially regarding early access to yet unapproved treatments.